First-Line Breast Cancer Approval Opens The Door For Pfizer’s Palbociclib
This article was originally published in The Pink Sheet Daily
Executive Summary
The CDK 4/6 inhibitor Ibrance (palbocliclib) just got its first approval in first-line metastatic breast cancer and Pfizer is losing no time on development, with trials of other indications planned or ongoing, including different tumor types.
You may also be interested in...
10 Triumphant Drug Launches Of The Decade
The view from 2020: Scrip looks back at the most successful commercial launches of the decade.
And Then There Were Three: Lilly's Verzenio Approved For Breast Cancer
Lilly will be offering its Verzenio – the third CDK4/6 inhibitor to reach the US market – at a comparable list price to Pfizer's Ibrance and Novartis' Kisqali. FDA granted the drug a swift approval, just two months after it was accepted for priority review.
Lilly Preps Abemaciclib To Take On Ibrance; Differentiation Still A Question
The CDK4/6 inhibitor showed progression-free survival in patients with breast cancer in an interim analysis, and Lilly plans to begin global regulatory submissions for the drug in the second quarter.